Jump to content

XF-73: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Chembox: rm/replace deprecated params. Fix unknown parameters (via AWB script)
Rescuing 1 sources, flagging 0 as dead, and archiving 3 sources. #IABot
Line 30: Line 30:
'''XF-73 (Exeporfinium chloride)''' is an experimental drug candidate. It is an [[anti-microbial]] which works via weakening bacteria cell walls.<ref name=tmt/> It is a potential treatment for [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA) and possibly ''[[Clostridium difficile]]''. It is being [[drug development|developed]] by Destiny Pharma Ltd.<ref>[http://www.destinypharma.com/xf73.shtml Destiny Pharma - XF-73] (shows molecular structure)</ref><ref>[http://www.blackwellpublishing.com/eccmid18/abstract.asp?id=68457 European Society of Clinical Microbiology and Infectious Diseases. XF-73], Apr 2008</ref><ref>[http://www.independent.co.uk/news/science/scientists-on-brink-of-cure-for-superbug-830345.html Scientists 'on brink of cure' for superbug], ''The Independent'', 18 May 2008</ref>
'''XF-73 (Exeporfinium chloride)''' is an experimental drug candidate. It is an [[anti-microbial]] which works via weakening bacteria cell walls.<ref name=tmt/> It is a potential treatment for [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA) and possibly ''[[Clostridium difficile]]''. It is being [[drug development|developed]] by Destiny Pharma Ltd.<ref>[http://www.destinypharma.com/xf73.shtml Destiny Pharma - XF-73] (shows molecular structure)</ref><ref>[http://www.blackwellpublishing.com/eccmid18/abstract.asp?id=68457 European Society of Clinical Microbiology and Infectious Diseases. XF-73], Apr 2008</ref><ref>[http://www.independent.co.uk/news/science/scientists-on-brink-of-cure-for-superbug-830345.html Scientists 'on brink of cure' for superbug], ''The Independent'', 18 May 2008</ref>


It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.<ref name=tmt>[http://www.themoneytimes.com/featured/20100920/promising-new-drug-xf73-kills-superbugs-within-5-minutes-id-10129029.html Promising new drug XF-73 kills superbugs within 5 minutes],{{dead link|date=October 2011}} 20 Sept 2010</ref><ref>[http://www.telegraph.co.uk/news/uknews/1981019/MRSA-UK-scientists-'close-to-a-treatment'.html MRSA: UK scientists 'close to a treatment], ''[[The Daily Telegraph]]''</ref>
It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.<ref name=tmt>[http://www.themoneytimes.com/featured/20100920/promising-new-drug-xf73-kills-superbugs-within-5-minutes-id-10129029.html Promising new drug XF-73 kills superbugs within 5 minutes], 20 Sept 2010 {{wayback|url=http://www.themoneytimes.com/featured/20100920/promising-new-drug-xf73-kills-superbugs-within-5-minutes-id-10129029.html |date=20110721204201 }}</ref><ref>[http://www.telegraph.co.uk/news/uknews/1981019/MRSA-UK-scientists-'close-to-a-treatment'.html MRSA: UK scientists 'close to a treatment], ''[[The Daily Telegraph]]''</ref>


Structurally it is a dicationic [[porphyrin]].<ref>[http://www.destinypharma.com/xfseries.shtml Destiny Pharma - XF series]</ref>
Structurally it is a dicationic [[porphyrin]].<ref>[http://www.destinypharma.com/xfseries.shtml Destiny Pharma - XF series]</ref>

Revision as of 01:15, 24 January 2016

XF-73
Identifiers
3D model (JSmol)
ChemSpider
  • InChI=1S/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
    Key: BXHQXSXRVAELBC-XRFOENPRSA-L
  • InChI=1/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;;
    Key: BXHQXSXRVAELBC-NDLTUMITBE
  • C[N+](C)(C)CCCOC(C=C1)=CC=C1/C(C2=CC=C(/C=C3C=CC(/C(C4=CC=C(OCCC[N+](C)(C)C)C=C4)=C(N/5)/C=CC5=C\6)=N/3)N2)=C7N=C6C=C/7.[Cl-].[Cl-]
Properties
C44H50Cl2N6O2
Molar mass 765.82 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]

It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][5]

Structurally it is a dicationic porphyrin.[6]

References

  1. ^ a b Promising new drug XF-73 kills superbugs within 5 minutes, 20 Sept 2010 Template:Wayback
  2. ^ Destiny Pharma - XF-73 (shows molecular structure)
  3. ^ European Society of Clinical Microbiology and Infectious Diseases. XF-73, Apr 2008
  4. ^ Scientists 'on brink of cure' for superbug, The Independent, 18 May 2008
  5. ^ MRSA: UK scientists 'close to a treatment, The Daily Telegraph
  6. ^ Destiny Pharma - XF series
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=XF-73&oldid=701351734"